Prayus Tailor, MD
Nephrology · Newark, DENPI 1679552764
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Nxstage Medical, Inc. accounts for 64.0% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $37,011 and has fallen 92.8% since, to $2,650 in 2025. Among nephrology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 585 payments — averaging $217.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nxstage Medical, Inc.$82K
- AstraZeneca$13K
- Fresenius USA Marketing, Inc.$10K
- GSK$8K
- Aurinia Pharma U.S., Inc.$4K
- Bayer$3K
- plus $8K from 31 others
What the payments were for
- Consulting fees$32,38025%
- Speaking & faculty fees$74,14058%
- Travel & lodging$7,4616%
- Food & beverage$13,40011%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nxstage Medical, Inc. | 99 | $81,536 |
| AstraZeneca(2 entities) | 63 | $13,209 |
| Fresenius USA Marketing, Inc. | 79 | $9,997 |
| GSK | 19 | $8,202 |
| Aurinia Pharma U.S., Inc. | 11 | $3,910 |
| Bayer | 28 | $2,774 |
| Amgen(2 entities) | 50 | $2,703 |
| Mallinckrodt Hospital Products Inc. | 29 | $811 |
| Vifor Pharma, Inc. | 29 | $674 |
| Otsuka America Pharmaceutical, Inc. | 28 | $548 |
| Travere Therapeutics, Inc. | 25 | $512 |
| Calliditas Therapeutics US Inc. | 16 | $415 |
| Novartis | 9 | $250 |
| Daiichi Sankyo Inc. | 14 | $244 |
| Ardelyx, Inc. | 12 | $239 |
| Sanofi | 11 | $194 |
| Akebia Therapeutics Inc | 9 | $164 |
| Novo Nordisk | 7 | $132 |
| Kyowa Kirin, Inc. | 5 | $117 |
| Boehringer Ingelheim | 7 | $111 |
| Mallinckrodt Enterprises LLC | 5 | $88 |
| Medtronic | 1 | $85 |
| ANI Pharmaceuticals, Inc. | 2 | $64 |
| Ultragenyx Pharmaceutical Inc. | 4 | $64 |
| OPKO Pharmaceuticals, LLC | 4 | $55 |
| Shield Therapeutics Inc | 1 | $55 |
| AMAG Pharmaceuticals, Inc. | 4 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Inari Medical, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $43 |
| Mozarc Medical US LLC | 1 | $38 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Daxor Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$78,638
- FARXIGA$11,883
- BENLYSTA$4,200
- LUPKYNIS$3,711
- System One$3,000
- Kerendia$2,334
- KRYSTEXXA$1,620
- LIBERTY SELECT CYCLER$148
- Veltassa$106
How this compares
$127,477 in reported general payments places this provider in the 95th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 67 | $97,211 |
| JardianceEmpagliflozin | 65 | $95,651 |
| KerendiaFinerenone | 20 | $31,227 |
| Cinacalcet Hcl | 23 | $18,658 |
| Potassium Citrate ErPotassium Citrate | 24 | $4,656 |
| Calcitriol | 147 | $2,843 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 12 | $2,790 |
| Losartan Potassium | 160 | $1,993 |
| Bumetanide | 23 | $1,157 |
| Amlodipine Besylate | 104 | $1,154 |
| Allopurinol | 96 | $1,127 |
| Potassium Chloride | 50 | $1,059 |
| Eplerenone | 11 | $971 |
| Furosemide | 127 | $856 |
| Metoprolol Succinate | 36 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $13,209 | $97,21167 claims |
| Boehringer IngelheimJardiance | $111 | $95,65165 claims |
| BayerKerendia | $2,774 | $31,22720 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $64 | $54920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- William DahmsNewark$94K
- Theodore SaadNewark$26K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.